Pfizer to Withdraw Sickle-Cell Drug Oxbryta From Worldwide Markets. Decision comes two years after acquiring the drug’s parent company, Global Blood Therapeutic, in a $5.4 billion deal. By .

Pfizer Inc. (NYSE: PFE) announced ... Patients, physicians, pharmacists, or other healthcare professionals with additional questions about OXBRYTA should contact Pfizer Medical Information 1-800 ...

Patients, physicians, pharmacists, or other healthcare professionals with additional questions about OXBRYTA should contact Pfizer Medical Information 1-800-438-1985.

In the second quarter of 2024, Oxbryta generated sales of $92 million, up 20% year-over-year.Pfizer added Oxbryta to its portfolio via its $5.4 billion buyout of Global Blood Therapeutics in 2022. ...

Pfizer said Wednesday that it was removing Oxbryta, a pill for the treatment of sickle cell disease, from all markets globally due to high risks of severe safety events, including deaths.

Pfizer (NYSE:PFE) has voluntarily withdrawn all lots of its sickle cell disease drug Oxbryta, also known as voxelotor, over safety concerns. The pharmaceutical giant said Oxbryta will be withdrawn ...

(Reuters) - Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts ...

SAN DIEGO — Pfizer’s abrupt withdrawal of its sickle cell drug Oxybryta over safety concerns was called “tone deaf” during a panel discussion among sickle cell experts Saturday at STAT@ASH ...

Pfizer Inc. announced today that it is voluntarily withdrawing all lots of OXBRYTA ® for the treatment of sickle cell disease at this time, in all markets where it is approved.

Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts said. Oxbryta ...

Oxbryta was the centerpiece of Pfizer's $5.4 billion buyout of Global Blood Therapeutics in 2022, one of a number of deals bankrolled by the pandemic-era windfall.